BioMarin's (BMRN) Confidence in Drisapersen Approvability Has Increased, Jefferies Says
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Sarepta Therapeutic (SRPT) PT Raised to $45 at Roth Capital
May 20, 2015 6:23 AM EDTRoth Capital analyst Debjit Chattopadhyay reiterated a Buy and boosted his price target on Sarepta Therapeutic (NASDAQ: SRPT) to $45.00 (from $22.00) following the rolling NDA submission with the FDA for eteplirsen.
Chattopadhyay commented, "Sarepta's meeting with the FDA has culminated into a... More
